Figure 4.
Figure 4. Improved cytolytic function following stimulation with OX40L mRNA–cotransfected DCs. (A) Priming of PSA epitope–specific CTLs using PSA mRNA– or PSA-mRNA/OX40L mRNA–cotransfected DCs as stimulators. CTLs were generated using the indicated stimulators. After 7 days, CTLs were restimulated with PSA-HLA A0201 epitope VISNDVCAQV or control peptide HLSTAFARV, and interferon-γ release was determined by ELISA. (B) PBMCs from a healthy HLA-A0201–positive volunteer were stimulated twice with lymph node carcinoma of the prostate (LNCaP) RNA–transfected DCs (□) or with LNCaP/OX40L mRNA–cotransfected DCs (▪) to generate CTLs. These CTLs were then used in cytolytic assays using DC targets transfected with the following mRNAs: LNCaP RNA, PSA mRNA, GFP mRNA, and OX40L mRNA. Representative results from 3 healthy donors are shown. Results are presented as the mean value of cytokine secretion or target cell lysis with SD (error bars) calculated from triplicate wells.

Improved cytolytic function following stimulation with OX40L mRNA–cotransfected DCs. (A) Priming of PSA epitope–specific CTLs using PSA mRNA– or PSA-mRNA/OX40L mRNA–cotransfected DCs as stimulators. CTLs were generated using the indicated stimulators. After 7 days, CTLs were restimulated with PSA-HLA A0201 epitope VISNDVCAQV or control peptide HLSTAFARV, and interferon-γ release was determined by ELISA. (B) PBMCs from a healthy HLA-A0201–positive volunteer were stimulated twice with lymph node carcinoma of the prostate (LNCaP) RNA–transfected DCs (□) or with LNCaP/OX40L mRNA–cotransfected DCs (▪) to generate CTLs. These CTLs were then used in cytolytic assays using DC targets transfected with the following mRNAs: LNCaP RNA, PSA mRNA, GFP mRNA, and OX40L mRNA. Representative results from 3 healthy donors are shown. Results are presented as the mean value of cytokine secretion or target cell lysis with SD (error bars) calculated from triplicate wells.

Close Modal

or Create an Account

Close Modal
Close Modal